Pancreatic Cancer Vaccine; AI Collaboration for Managing Epilepsy
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of Texas Tech Health El Paso, look at the top medical...
Pancreatic cancer researchers are exploring a new vaccine targeting KRAS, a mutated protein found in certain types of cancer cells. In a recent study, the experimental vaccine camupepimut was administered to patients with pancreatic adenocarcinoma, or pancreatic cancer, in a randomized 2:1 ratio with standard-of-care observation.
The trial aimed to measure disease-free survival, but unfortunately, the intervention arm did not meet its endpoint after six months. However, the study did yield some promising results, such as increased baseline circulating tumor DNA positivity, which could potentially serve as a valuable biomarker for monitoring cancer progression.
Further research is needed to determine the vaccine's efficacy and long-term benefits for pancreatic cancer patients.
Written by urgent.news from MedPage Today's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
